> ## Content Index > Fetch the complete content index at: https://nexi.fund/llms.txt > Use this file to discover other available public pages before exploring further. # Capricor Therapeutics Faces FDA AdCom Split โ€” 3-9 Vote Against Deramiocel for Duchenne - URL: https://nexi.fund/capricor-deramiocel-fda-decision-2026/ - Published: 2026-07-30T10:30:48.000Z - Updated: 2026-07-30T10:39:24.000Z - Description: FDA AdCom voted 9-3 against Capricor deramiocel for Duchenne cardiomyopathy. PDUFA August 22. Lancet published positive HOPE-3 data same day. - Author: Nexi.fund Labs - Tags: Biotech & Health, #mode-1, #hook-number, #track-E, #brand-heavy An FDA advisory committee voted 9โ€“3 against recommending Capricor Therapeutics' cell therapy deramiocel for Duchenne muscular dystrophy. The FDA itself decides by August 22. ๐ŸŽฏ The Cellular, Tissue, and Gene Therapies Advisory Committee voted 9โ€“3 that the available evidence does not show deramiocel is effective for Duchenne cardiomyopathy. The FDA disagreed with Capricor's statistical analysis before the meeting, arguing the Phase 3 HOPE-3 trial did not meet its primary endpoint under the pre-specified analysis plan. The Lancet published the HOPE-3 results on the same day, lending independent peer-reviewed validation to Capricor's positive claims. This created a rare split between academic publication and regulatory interpretation. ## What Is Deramiocel and Why It Matters Deramiocel (CAP-1002) is an allogeneic cardiac-derived cell therapy; cells cultured from donor heart tissue, then infused intravenously. Unlike gene therapies that correct the underlying dystrophin mutation, deramiocel works through immunomodulatory and anti-fibrotic mechanisms: it reduces inflammation and scar tissue in muscle, including the heart. Duchenne muscular dystrophy affects roughly 1 in 3,500 male births. Patients lose the ability to walk by early adolescence and typically die in their 20s or 30s from respiratory or cardiac failure. No approved therapy targets the cardiac manifestation, cardiomyopathy, which is the leading cause of death in Duchenne. Capricor, a San Diego-based biotech with a market cap of roughly $0.4 billion, submitted a Biologics License Application supported by the Phase 2 HOPE-2 trial and its open-label extension. The FDA issued a Complete Response Letter in July 2025, rejecting the initial application. It then ran the pivotal Phase 3 HOPE-3 trial and resubmitted. The FDA accepted the resubmission in March 2026 and set a PDUFA date of August 22, 2026. ## The FDA's Dispute With Capricor's Analysis In briefing documents published July 27, the FDA challenged Capricor's core claim. The agency wrote that HOPE-3 did not meet its primary endpoint under the final pre-specified Statistical Analysis Plan. Capricor, the FDA argued, switched to a different version of the SAP (version 3.0) after unblinding, and it was this post-hoc version that produced the statistically significant result. > For reasons we do not understand why, the FDA has seized upon that unfinished, unsigned draft SAP and performed numerous analyses based on this incomplete draft. This would be like your professor grading your term paper on an early draft you have never even submitted.โ€” Linda Marbรกn, CEO, Capricor Therapeutics Its position is that SAP version 3.0 was the pre-specified plan all along and that the FDA's briefing used an earlier draft. The dispute hinges on whether the primary analysis population includes all randomized patients or only those with measurable cardiac function at baseline, a methodological distinction that changed the p-value from significant to not. ## The Lancet Publication โ€” A Conflicting Signal On the same day as the AdCom meeting, The Lancet published the HOPE-3 results after independent peer review. The paper concluded that deramiocel slowed upper limb function decline by 54 percent versus placebo (PUL 2.0, p=0.03) and showed clinically meaningful cardiac benefit. The Lancet's editorial process is one of the most rigorous in medicine, and its decision to publish suggests the data survive expert scrutiny โ€” even if the FDA's statisticians read the same numbers differently. The academic gatekeeper validated the company's claims. The regulatory gatekeeper did not. For biotech investors, that split is the central uncertainty between now and August 22. โš ๏ธ **The SAP dispute is not unique to Capricor.** The FDA has increasingly scrutinized post-hoc analysis changes in rare-disease trials where small sample sizes make p-values sensitive to population definitions. For investors, the question is whether the agency will treat this as a procedural violation or an opportunity to apply regulatory flexibility. ## What the AdCom Vote Means Advisory committee votes are non-binding. The FDA follows them roughly 78 percent of the time, but the rate varies by division. The Cellular, Tissue, and Gene Therapies Advisory Committee, which reviewed deramiocel, has a below-average concordance rate; the FDA has overruled negative CTGTAC votes in several prior cell therapy decisions. The vote itself was 9โ€“3 against, not unanimous. Three panel members saw sufficient evidence. The discussion revealed that the disagreement was about statistical methodology, not safety. No committee member raised concerns about deramiocel's safety profile. For serious diseases with no alternatives, the FDA has sometimes applied flexibility in cell therapy decisions. ### What happens between now and August 22 The FDA will consider the committee's discussion, the written record, the HOPE-3 data, and the totality of evidence. It may approve, issue a second Complete Response Letter, or require an additional trial. It has indicated it expects a Priority Review Voucher if approved. ๐Ÿ”ฎ **What happens if the FDA approves deramiocel by August 22?** Probability: 35% โ€” Six weeks between a negative AdCom and a positive FDA decision is short but not unprecedented. The Lancet publication and the methodology-first nature of the disagreement give it a path. The CRL history and the FDA's own briefing documents argue the other way. #### โœ… Arguments for approval The Lancet publication validates the data independently. No approved therapy targets Duchenne cardiomyopathy; the unmet need is clear. CTGTAC has been overruled before on cell therapy decisions. Safety profile is clean; the dispute is about statistics, not efficacy. **Confirmation criteria:** FDA issues approval order before August 22 deadline. #### โŒ Arguments against approval The FDA's own analysis found the primary endpoint not met under the pre-specified SAP. A second CRL would be consistent with the agency's increasing scrutiny of post-hoc analysis changes in rare-disease trials. The AdCom vote was decisive at 9โ€“3, and the FDA follows AdCom recommendations most of the time. Its market cap already prices in substantial approval probability (\~$0.4B for a single-asset rare-disease biotech). **Disconfirmation criteria:** FDA issues a second CRL or requests an additional trial before August 22\. ## Development Scenarios #### ๐ŸŸข Optimistic scenario (15%) FDA approves deramiocel by August 22 with a label for Duchenne cardiomyopathy. Capricor receives a Priority Review Voucher. The stock re-rates to $15+ on first-ever cell therapy approval for DMD. **Implications:** Opens the door for cell therapy in rare neuromuscular diseases. Validates allogeneic cardiac-derived cell platform for other indications. #### ๐ŸŸก Base-case scenario (50%) FDA issues a second CRL requesting additional analysis or a confirmatory trial. Its stock drops 40โ€“60%. The science is not questioned, but the statistical dispute delays market entry by 18โ€“24 months. **Implications:** Capricor needs additional capital to fund a confirmatory trial. The Duchenne community waits longer for a cardiac-targeted therapy. #### ๐Ÿ”ด Pessimistic scenario (35%) FDA issues a second CRL with significant new requirements (new Phase 3 trial, not just confirmatory analysis). Its stock drops 70%+. The company may not have the cash runway to complete another trial without dilution or partnership. **Implications:** Questions the viability of cell therapy for DMD. The CRL could also affect other cardiac-derived cell therapy programs in development. ## Key Signals to Track ๐Ÿ“Š **Key signals to track** FDA communication before August 22: any update on the review timeline or additional data requests would signal direction. Its Q2 2026 earnings call: cash position and any partnership discussion will indicate contingency planning. Duchenne patient advocacy response: PPMD has scheduled a town hall for August 4; community pressure can influence rare-disease decisions. Comparator FDA decisions in cell therapy: the agency's treatment of other allogeneic cell therapy BLAs this year sets precedent. ## Sources [ FDA adcom declines to recommend Capricor's Duchenne drug Live coverage of the July 29 CTGTAC advisory committee meeting, including the 9-3 vote and FDA briefing document analysis. STAT News ](https://www.statnews.com/2026/07/29/capricor-therapeutics-deramiocel-fda-review-meeting-live-blog/?ref=nexi.fund) Primary source for AdCom vote count, FDA analysis, and committee discussion. [ FDA reviewers vote against approval of Capricor's DMD therapy in chaotic adcomm meeting BioSpace's detailed account of the meeting dynamics, the SAP dispute, and the broader regulatory context. BioSpace ](https://www.biospace.com/fda/fda-reviewers-vote-against-approval-of-capricors-dmd-therapy-in-chaotic-adcomm-meeting?ref=nexi.fund) Provides context on the FDA-Capricor SAP disagreement and the CRL history. [ Thank You for Raising Your Voices During the Deramiocel FDA Advisory Committee Meeting Parent Project Muscular Dystrophy's post-meeting update, including patient testimony context and the August 4 town hall announcement. Parent Project Muscular Dystrophy ](https://www.parentprojectmd.org/thank-you-for-raising-your-voices-during-the-deramiocel-fda-advisory-committee-meeting?ref=nexi.fund) Patient advocacy perspective on the AdCom outcome and next steps for the Duchenne community.